Age-related disparity of survival outcomes and treatment-related adverse events in patients with metastatic colorectal cancer

Author:

Meng Lingbin,Thapa Ram,Delgado Maria G.,Gomez Maria F.,Ji Rui,Knepper Todd C.,Hubbard Joleen M.,Wang Xuefeng,Permuth Jennifer B.,Kim Richard D.,Laber Damian A.,Xie Hao

Abstract

AbstractBackgroundWhile the incidence of newly diagnosed early-onset colorectal cancer has been increasing, age-related disparity of survival outcome and treatment-related adverse events in patients with metastatic CRC (mCRC) has been inadequately studied with inconclusive findings. In this study, we aimed to evaluate such age-related disparity in this patient population.MethodsWe used individual patient data from three clinical trials (Study 1:NCT00272051, NCT 00305188 and Study 2:NCT00364013) in Project Data Sphere. All patients were diagnosed with mCRC and received first-line 5-fluorouracil and oxaliplatin. Clinical and genomic data of 763 patients with mCRC from Moffitt Cancer Center were used to assess genomic alterations and serve as an external and real-world validation cohort to evaluate overall survival (OS) disparity. Survival outcomes and treatment-related adverse events were estimated and compared in patients among three age groups: <50, 50-65, and >65 years.ResultsAmong 1223 patients from previous clinical trials, 179 (14.6%) were younger than 50 years. These patients had significantly shorter progression-free survival (PFS) (HR=1.46; 95%CI=1.22–1.76;p<0.001) and OS (HR=1.48; 95%CI=1.19–1.84;p<0.001) compared to patients in the 50-65 group of both Study 1 and Study 2 after adjustment for gender, race, and performance status. Significantly shorter OS was also observed in patients from the <50 group in the Moffitt cohort. When compared to other age groups, the <50 group had significantly higher incidence of nausea/vomiting (69.3% vs 57.6% vs 60.4%,p=0.019), severe abdominal pain (8.4% vs 3.4% vs 3.5%,p=0.018), severe anemia (6.1% vs 1.0% vs 1.5%,p<0.001), and severe rash (2.8% vs 1.2% vs 0.4%,p=0.047), but significantly lower incidence of fatigue, severe diarrhea, severe fatigue, and severe neutropenia. The <50 group had earlier onset of nausea/vomiting (1.0 vs 2.1 vs 2.6 weeks,p=0.012), mucositis (3.6 vs 5.1 vs 5.7 weeks,p=0.051), and neutropenia (8.0 vs 9.4 vs 8.4 weeks,p=0.043), and shorter duration of mucositis (0.6 vs 0.9 vs 1.0 weeks,p=0.006). In the <50 group, severe abdominal pain and severe liver toxicity were associated with both shorter OS and PFS. In contrast, moderate peripheral neuropathy was associated with longer PFS. Our genomic data showed that the <50 group had higher prevalence ofCTNNB1mutation (6.6% vs 3.1% vs 2.3%,p=0.047),ERBB2amplification (5.1% vs 0.6% vs 2.3%,p=0.005), andCREBBPmutation (3.1% vs 0.9% vs 0.5%,p=0.050), but lower prevalence ofBRAFmutation (7.7% vs 8.5% vs 16.7%,p=0.002).ConclusionsPatients with early-onset mCRC had worse survival outcome and unique adverse-event patterns, which could be partially attributed to distinct genomic profiles. Our findings might improve an individualized approach to chemotherapy, counseling, and management of treatment-related adverse events in this patient population.

Publisher

Cold Spring Harbor Laboratory

Reference52 articles.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3